Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer v. Chronimed

This article was originally published in The Gray Sheet

Executive Summary

Firms announce Dec. 7 settlement of patent litigation under which both parties will continue to market their products,and Chronimed's test strips will include a redesign of the DiaScreen leukocyte test. Bayer Diagnostics had filed suit in March 1999, alleging that the DiaScreen leukocyte test infringed its Multistix line of urine test strips (1"The Gray Sheet" March 15, 1999, p. 29)

You may also be interested in...



Chronimed Initiates Preemptive Defense, Bayer Infringement Suit Follows

Chronimed's DiaScreen urinalysis test strips for leukocytes do not incorporate analytical processes or agents claimed in Bayer's U.S. patent covering glucose test strip technology, Chronimed maintains in a declaratory judgment action filed against Bayer in Minneapolis federal court.

Big Pharma BD Execs Tell Start-Ups: Don’t Be Afraid To Ask Us For Help

Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.

Transformation Into Viatris Not Seen As The Solution Mylan Needs

Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.

UsernamePublicRestriction

Register

MT014215

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel